J. Goldman & Co’s Structure Therapeutics GPCR Stock Holding History

J. Goldman & Co’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,601	Closed	-$946K	–	750
2025 Q4	$946K	Buy	+13,601	New	+$555K	0.02%	392
2025 Q1	–	Sell	-16,873	Closed	-$458K	–	534
2024 Q4	$458K	Buy	+16,873	New	+$599K	0.01%	367

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

J. Goldman & Co's GPCR Position: Q1 2026 in Review

J. Goldman & Co sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 13,601 shares — an estimated $946K sold.

J. Goldman & Co first reported a position in GPCR in Q4 2024 and held it in 2 quarters. The position peaked at $946K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

J. Goldman & Co reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 13,601 Structure Therapeutics shares in Q1 2026, an estimated $946K.
J. Goldman & Co first reported a position in Structure Therapeutics in Q4 2024 and held it in 2 quarters.
J. Goldman & Co's Structure Therapeutics position peaked at $946K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.